Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) announces that the Company has successfully completed the planned human factors validation study assessing the revised Instructions for Use for Sofpironium Bromide gel https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02753854-6A1186430 #shorts
SUH
0.04
90.5%
EEL
0.001
-50%
MEI
0.13
88.4%
TMS
0.005
-50%
EQS
0.03
66.7%
OLI
0.003
-40%
NWM
0.015
66.7%
ASR
0.002
-33.3%
ASM
0.775
63.2%
KAL
0.052
-33.3%
VHM
0.38
60.3%
PSL
0.006
-33.3%
ENV
0.008
60%
BPM
0.028
-26.3%
PGY
0.008
60%
MRQ
0.003
-25%
WIN
0.022
57.1%
PIL
0.003
-25%
REE
0.036
56.5%
RLG
0.003
-25%
M2R
0.003
50%
TMK
0.003
-25%
SLZ
0.009
50%
IMI
0.013
-23.5%
PEK
0.16
45.5%
CYB
0.075
-20.2%
SRL
0.71
43.4%
CR3
0.012
-20%
BCM
0.01
42.9%
DGR
0.004
-20%
VMM
0.355
42%
RGL
0.004
-20%
NTU
0.04
37.9%
SPQ
0.004
-20%
PAT
0.07
37.3%
VRC
0.004
-20%
SGQ
0.026
36.8%
AKM
0.23
-19.3%
PSC
0.15
36.4%
IR1
0.155
-18.4%
